Pathological regional adipose tissue accumulation associated with
HIV-associated dysmorphic/dysmetabolic syndrome (HADDS) which may occur
with or without subcutaneous adipose tissue lipodystrophy (and which is
also described as HIV-associated adipose redistribution syndrome or HARS
and other specific medical terms), is treated by administering an
effective amount of human growth hormone or other substance which binds to
and initiates signalling of the hGH receptor. Alternatively, a substance
which stimulates production of endogenous hGH, such as human growth
hormone releasing hormone, may be administered. HADDS and related
syndromes include abnormal adipose tissue accumulation in the visceral,
submandibular, supraclavicular, pectoral, mammary and/or dorsocervical
(buffalo hump) area, and/or with subcutaneous lipomas, with or without
associated metabolic or other physiologic abnormalities.
